...
首页> 外文期刊>International Journal of Hematology and Oncology >Invivo Hemostatic Effect of Ankaferd Blood Stopper in Rat Major Renal Trauma Model: Controlled Trial of Novel Hemostatic Agent
【24h】

Invivo Hemostatic Effect of Ankaferd Blood Stopper in Rat Major Renal Trauma Model: Controlled Trial of Novel Hemostatic Agent

机译:Ankaferd止血剂在大鼠主要肾脏创伤模型中的体内止血作用:新型止血剂的对照试验

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Ankaferd Bloodstopper (ABS) which is a medicinal product has been approved in the control of hemorrhage externally, dental surgery bleedings in Turkey to control the bleeding in renal trauma model was evaluated. Twelve Wistar rats were divided into two groups. Group I (GI),control, Group II (GII), study group. One cm2 tissue was resected. ABS solution was applied to resected area in study group. Standard suture was applied to control group. Bleeding time, number of ABS, live condition were evaluated. Histopathologic evaluations were completed. Mean time of bleeding control was 3.2 (2.4-3.6) min in GII, no difference with GI (p> 0.05). In GII, active hemostasis was provided. Mean number of ABS gout was 6.0 (5-8). Glomerular necrosis was detected with higher rate in GI compared with GII. Erythrocyte aggregation was confirmed in GII. Calcification was formed significantly in GI compared GII (p< 0.05). ABS could be an effective agent to stop active major bleeding in renal trauma model.
机译:药品Ankaferd Bloodstopper(ABS)已被批准用于控制外部出血,评估了土耳其的牙科手术出血以控制肾脏创伤模型的出血。将十二只Wistar大鼠分成两组。第一组(GI),对照组,第二组(GII),研究组。切除一平方厘米的组织。将ABS溶液应用于研究组的切除区域。将标准缝合线用于对照组。评价出血时间,ABS数量,生活状况。组织病理学评估已完成。在GII中,平均出血控制时间为3.2(2.4-3.6)min,与GI无差异(p> 0.05)。在GII中,提供了主动止血功能。 ABS痛风的平均数为6.0(5-8)。与GII相比,GI中发现肾小球坏死的发生率更高。在GII中证实了红细胞聚集。与GII相比,GI明显形成钙化(p <0.05)。在肾脏外伤模型中,ABS可能是阻止活动性大出血的有效药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号